Results
Of the 65 participants, 8 were excluded from the cognitive component of
the study due to low scores on the Mini-Mental State Exam, and 9 with
incomplete data were excluded. Results of the remaining 48 patients were
analyzed.
The mean age of the patients was 69.08 ± 4.77 years, and the mean body
mass index was 25.73 ± 2.93 kg/m2. Demographic
characteristics of the patients are shown in Table 1. The mean
pretreatment, third month, and sixth month total PSA levels were 46.46 ±
37.83 ng/mL, 1.41 ± 3.31 ng/mL, and 0.08 ± 0.14 ng/mL, respectively. The
mean testosterone level significantly decreased in the 3- (21.61 ± 9.09
ng/dL) and 6-month controls (12.25 ± 6.45 ng/dL) from the pretreatment
level (381.40 ± 157.53 ng/dL) (p = 0.001) (Table 2). The transrectal
ultrasound guided prostate biopsy Gleason scores of the patients are
shown in Figure 1.
The mean baseline, 3-month and 6-month SDMT scores were 25.84 ± 17.54,
23.30 ± 17.40 and 23.23 ± 16.03, respectively (p = 0.092). The mean
pretreatment, 3-month, and 6-month CVLT-II scores were 32.68 ± 10.60,
31.56 ± 10.73, 29.43 ± 11.30, respectively (p= 0.297). The mean
baseline, 3-month, and 6-month BVMT-R scores were 17.63 ± 11.23, 16.57 ±
11.13, and 16.12 ± 10.21, respectively (p = 0.731). The mean baseline,
3-month, and 6-month time for the TMT was 221.56 ± 92.44 s, 225.78 ±
87.47 s and 244.68 ± 77.37 s, respectively (p = 0.731) (Table 3). The
mean baseline, 3-month, and 6-month BDI scores were 11.15 ± 6.40, 11.78
± 5.45 and 12.00 ± 10.58, respectively (p = 0.61).